Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Drug distributor McKesson Corp on Wednesday raised its annual profit forecast, banking on strong demand for specialty medicines.

McKesson lifts annual profit forecast after strong quarterly results

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2024 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 1st at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live a.

McKesson Corporation Reports Fiscal 2024 Second Quarter Results and Raises Full Year Guidance

Cigna

UnitedHealth Group

Blue-chip companies are very well established, have an excellent reputation and boast a history of providing investors with consistent returns. Blue-chip stocks are a must for investors because they are some of the most stable companies in the market and typically have lower volatility than other companies with not-so-stellar reputations.

Top 3 Blue-Chip Stocks in the Healthcare Industry

McKesson earnings are on tap, with rival medical products distributors Cencora and Cardinal Health due soon. They're stealth ways to play the weight-loss drug boom

Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals

Lamb Weston Hlds

New Jersey Resources

PepsiCo

Procter & Gamble

At this juncture, we have narrowed our search to five stocks from defensive sectors like utilities, consumer staples and healthcare. These stocks are: NJR, LW, MCK, PEP, PG.

5 Safe Stocks to Buy Amid Uncertainty on Wall Street

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

Akamai Technologies

Allstate

Amgen

Arista Networks

Axon Enterprise

Cboe Global Markets

Constellation Energy Corp

Diamondback Energy

Humana

Eli Lilly

Marathon Petroleum

NRG Energy

Progressive

Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.

Investors Scurry To Buy 14 Soaring Stocks As Market Sells Off

Applied Industrial Technologies

Universal Display

PBF Energy

Toll Brothers

Invest in companies like Toll Brothers (TOL), Universal Display (OLED), Applied Industrial Technologies (AIT), PBF Energy (PBF) and McKesson (MCK) to make the most of their higher efficiency levels.

5 Stocks Backed by High Efficiency to Boost Portfolio Returns

Automatic Data Processing

Ares Management

Caterpillar

Coterra Energy

CubeSmart

Deere & Company

EOG Resources

Intuit

JPMorgan Chase & Co

Kinsale Capital Group

Mastercard

Microsoft

NXP Semiconductors

Old Dominion Freight Line

PulteGroup

Vanguard Dividend Appreciation ETF

Vulcan Materials

Zoetis

We pick high-growth dividend stocks that have rapidly grown their dividends in the recent past rather than offering a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. We provide criteria for selecting high-growth dividend stocks, offering a step-by-step guide on structuring a portfolio based on this strategy.

Our Top 10 Picks For Dividend Growth Stocks - October 2023

McKesson Corp's MCK impressive performance stands out amidst a decline in the S&P 500 index.

McKesson Aims For The $500 Milestone After Shattering Previous Record Highs And Outperforming The S&P 500! - McKesson (NYSE:MCK)

Bristol-Myers

Johnson & Johnson

Pfizer

Walgreens

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

Rite Aid

Rite Aid Corp

Pharmacy chain Rite Aid has settled a critical dispute with drug supplier McKesson Corp to ensure that customers' prescriptions will continue to be filled during Rite Aid's bankruptcy, attorneys said on Tuesday.

Bankrupt Rite Aid resolves drug supply dispute with McKesson

McKesson Corp. MCK, +0.73% disclosed Monday that it doesn't expect drugstore chain Rite Aid Corp.'s RAD, -16.81% bankruptcy announced over the weekend to have a material impact on its adjusted earnings outlook for fiscal 2024. The health care supply and retail pharmacy company added that Rite Aid's bankruptcy isn't expected to have a material impact on its liquidity position or operations.

McKesson doesn't expect Rite Aid's bankruptcy to have much affect on profit outlook, liquidity

McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know

Align Technology

Henry Schein

West Pharmaceutical Services

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

4 Stocks to Buy From the Prospering Dental Supplies Industry

Novartis

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-average support.

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2024 financial results after market close on Wednesday, November 1, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide pr.

McKesson Corporation Announces Second Quarter Fiscal 2024 Earnings Release Date

Applied Materials

Arcos Dorados Hlds

NetEase

Applied Materials (AMAT), PulteGroup (PHM), Arcos Dorados (ARCO), McKesson (MCK) and NetEase (NTES) could be compelling picks for investors in the current scenario.

Dive Into Dividends: Top 5 Bargain Growth Stocks to Buy

News for McKesson Stock (MCK)